The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Can menopausal hormone therapy be administered to patients who have been treated for genital cancer?

Authors:

Zaidieva Ya.Z.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2023;23(2): 70‑75

DOI: 10.17116/rosakush20232302170

Read: 2907 times

Download PDF (RU)
Contact the author
Table of contents

CAN MENOPAUSAL HORMONE THERAPY BE ADMINISTERED TO PATIENTS WHO HAVE BEEN TREATED FOR GENITAL CANCER?
CAN MENOPAUSAL HORMONE THERAPY BE ADMINISTERED TO PATIENTS WHO HAVE BEEN TREATED FOR GENITAL CANCER?

To cite this article:

Zaidieva YaZ. Can menopausal hormone therapy be administered to patients who have been treated for genital cancer? Russian Bulletin of Obstetrician-Gynecologist. 2023;23(2):70‑75. (In Russ.)
https://doi.org/10.17116/rosakush20232302170

 
Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asse­ssment of the effect of meno­pause symptoms on women’s quality of life and their atti­tude to the mani­festations of meno­pause and meno­pausal hormone therapy. Russian Journal of Human Reproduction. 2025;(3):84-91
Abstract:

Rapid advances in oncology have led to an increase in the survival rate of cancer patients. The management of patients surviving treatment for gynecological malignancies poses a major challenge, as these diseases are hormone-dependent and menopausal hormone therapy (MHT) can increase the risk of recurrence. This article presents an analytical review of pro- and retrospective studies and guidelines regarding the prescription of MHT after treatment for gynecological malignancies. Current data indicate that MHT is contraindicated after treatment for breast and endometrial cancer. After treatment of ovarian cancer, MHT may be indicated but only after a risk/benefit assessment, while it is generally not contraindicated after treatment of vulvar, vaginal or cervical cancer. The decision to prescribe MHT in these patients should always be individualised.

Keywords:

menopausal hormonal therapy
cancer of reproductive system organs

Authors:

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Received:

18.04.2022

Accepted:

17.05.2022

Close metadata

References:

  1. Study of Womenʼs Health Across the Nation. Avis NE, Crawford SL, Greendale G. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531-539. 
  2. Gracia CR, Freeman EW. Onset of the menopause transition: The earliest signs and symptoms. Obstet Gynecol Clin North Am. 2018;45:585-597.  https://doi.org/10.1016/j.ogc.2018.07.002
  3. Bacon JL. The Menopausal transition. Obstet Gynecol Clin North Am. 2017;44:285-296.  https://doi.org/10.1016/j.ogc.2017.02.008
  4. Roberts H, Hickey M. Managing the menopause: An update. Maturitas. 2016;86:53-58.  https://doi.org/10.1016/j.maturitas.2016.01.007
  5. Langer RD. The evidence base for HRT: what can we believe? Climacteric. 2017;20:91-96.  https://doi.org/10.1080/13697137.2017.1280251
  6. Antoine C, Liebens F, Carly B. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod. 2007;22:616-622.  https://doi.org/10.1093/humrep/del393
  7. Untch M, Beckmann M W, Emons G. The LIBERATE Study: Hormone replacement Therapy with tibolone increases the risk of recurrence and metastases in breast cancer patients. Geburtshilfe Frauenheilkd. 2009;69:199-201. 
  8. Donders G, Neven P, Moegele M. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(R)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145:371-379. 
  9. Calvocoressi L, Stowe MH, Carter D. Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. Cancer Epidemiol. 2012;36:161-168. 
  10. Luo J, Cochrane BB, Wactawski-Wende J. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013;137:915-925. 
  11. Sourouni M. Hormonersatztherapie und duktales Carcinoma in situ. J Gynäkol Endokrinol CH. 2019;22:100-104. 
  12. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;(05):CD008830.
  13. Di Donato V, Palaia I, DʼAniello D. Does yormone replacement therapy impact the prognosis in endometrial cancer survivors? A Systematic review. Oncology. 2020;98:195-201. 
  14. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer. 2014;50:1628-1637.
  15. Crandall CJ, Hovey KM, Andrews CA. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womenʼs Health Initiative Observational Study. Menopause. 2018;25:11-20. 
  16. Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors-review of the literature. Pathol Oncol Res. 2020;26:63-78.  https://doi.org/10.1007/s12253-018-00569-x
  17. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol. 2015;139:355-362. 
  18. Eeles RA, Morden JP, Gore M. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial. J Clin Oncol. 2015;33:4138-4144. https://doi.org/10.1200/JCO.2015.60.9719
  19. Saeaib N, Peeyananjarassri K, Liabsuetrakul T. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev. 2020;(01):CD012559.
  20. Mau C, Untch M. Prophylactic Surgery: For Whom, When and How? Breast Care (Basel). 2017;12:379-384. 
  21. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106:1588-1599.
  22. Gordhandas S, Norquist BM, Pennington KP. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol. 2019;153:192-200. 
  23. Marchetti C, De Felice F, Boccia S. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A Meta-analysis. Crit Rev Oncol Hematol. 2018;132:111-115. 
  24. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol. 1987;26:169-177. 
  25. Angioli R, Luvero D, Armento G. Hormone replacement therapy in cancer survivors: Utopia? Crit Rev Oncol Hematol. 2018;124:51-60. 
  26. Vargiu V, Amar ID, Rosati A. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric. 2021;24:120-127.  https://doi.org/10.1080/13697137.2020.1826426
  27. Rauh LA, Pannone AF, Cantrell LA. Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care? Gynecol Oncol. 2017;147:597-600. 
  28. Sherman KJ, Daling JR, McKnight B. Hormonal factors in vulvar cancer. A case-control study. J Reprod Med. 1994;39:857-861. 
  29. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-881. 
  30. Somoye GO, Gull S. Adenocarcinoma of the vaginal vault following prolonged unopposed oestrogen hormone replacement therapy. J Obstet Gynaecol. 2005;25:220-221.  https://doi.org/10.1080/01443610500050991
  31. Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med. 2019;24:2515690X19829380.
  32. Sourouni M, Kiesel L. Hormone replacement therapy after gynaecological malignancies: a review article. Geburtshilfe und Frauenheilkunde. 2021;81:5:549-554.  https://doi.org/10.1055/a-1390-4353
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.